Loading news...
Low P/B screen spotlights IVZ, HRMY, CNXC, PAX and GPN as undervalued picks with solid growth potential heading into 2026.
Sandip Kapadia sold 3,746 shares directly for a total transaction value of approximately $139,171 on Jan. 26, 2026. Kapadia had sold all of his shares in Harmony Biosciences earlier in January, but his stock options and restricted stock units vested, bringing him back into partial ownership of the company.
Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.
Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.
Tech turmoil weighs on Wall Street, but CNXC, GPN, HRMY, and UHS stand out with low P/CF ratios and solid growth.
Four GARP stocks - including NEXA - pair discounted PEG ratios with strong growth potential, showing how value and growth can work together.
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Harmony Biosciences has thrived due to the success of its Wakix narcolepsy treatment. Harmony is looking to extend the life of the intellectual property behind Wakix through new versions of the compound pitolisant.
Harmony's approved narcolepsy drug Wakix has been a huge financial success. Controversy and litigation surrounding Wakix have held back the stock.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
The biotechnology area includes many stocks that command premium valuations because of their future prospects. So when a more attractively priced option appears, it's worth closer examination.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Campbell and CO Investment Adviser LLC lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 35.7% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 28,871 shares of the company's stock after selling 16,036 shares during the period. Campbell and CO Investment
Five low price-to-book stocks stand out for 2026, as undervalued valuations and solid growth outlooks put them on investors' radar.
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term gro.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CX Institutional lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 10.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 230,433 shares of the company's stock after buying an additional 22,650 shares during the quarter. CX Institutional owned about 0.40%